TrialReader


Bone Microstructure by Using HR-pQCT in Long Courses After Gastrectomy

NCT03251430 — Unknown, 114 participants, Kobayashi Shinichiro

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Assessment of Bone Microstructure by Using High-resolution Peripheral Quantitative Computed Tomography in Long Courses After Gastrectomy : a Prospective Observational Study

RegistryNCT03251430
StatusUnknown
Study typeObservational
Enrollment114 (Estimated)
SponsorKobayashi Shinichiro (Other)
ConditionsOsteoporosis, Sarcopenia, Gastric Cancer
Interventionsgastrectomy (Procedure)
Datesstart 2017-09-20, primary completion 2019-03-01 (estimated), completion 2019-03-31 (estimated), first posted 2017-08-16, last updated 2018-01-09
Locations1 site in Japan

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Osteoporosis All trials for Sarcopenia All trials of gastrectomy

-Summary

Osteoporosis after gastrectomy, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after gastrectomy. The aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in the long course after gastrectomy. In total gastrectomy and distal gastrectomy groups, at least 5 years should have elapsed since gastrectomy.

Expand all sections  ·  Collapse all

+Detailed description

The patients after gastrectomy loss appetite and decrease the weight. Total gastrectomy especially cause severe sarcopenia and metabolic change. Osteoporosis after gastrectomy, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after gastrectomy. The primary tools for assessing volumetric density and bone structure are quantitative computed tomography (QCT) and more recently, high-resolution peripheral quantitative computed tomography (HR-pQCT). However the validation of osteoporosis with HR-pQCT in the long course after gastrectomy remain elusive. The aim of the present study was to evaluate osteoporosis by using HR-pQCT in the long course after gastrectomy. In total gastrectomy and distal gastrectomy groups, at least 5 years should have elapsed since gastrectomy.

+Arms and interventions

ArmTypeInterventionsDescription
Control group38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
Distal Gastrectomy (DG) groupProcedure: gastrectomy38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
Total Gastrectomy (TG) groupProcedure: gastrectomy38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
  • gastrectomy (Procedure): Distal gastrectomy, Total gastrectomy

+Outcome measures

Primary outcomes

  • Comparing bone microstructure in control, DG, and TG groups [day1]: volumetric bone mineral density

Secondary outcomes

  • Comparing bone microstructure with sarcopenia [day1]: Correlation between bone mineral density in HR-pQCT and cross-sectional area of the abdominal psoas major muscle
  • Comparing bone microstructure with serum biomarkers of osteoporosis [day1]: Correlation between bone mineral density in HR-pQCT and biomarkers (25-hydroxyvitaminD, calcium, iPTH, P1NP, ICTP, TRACP5b)
  • Comparing bone microstructure with dual-energy X-ray absorptiometry [day1]: Correlation of bone mineral density between HR-pQCT and DXA
  • Comparing bone microstructure with quality of life (QOL-C30) [day1]: Patients will be asked to complete a short debriefing questionnaire covering questions (QOL-C30)
  • Comparing bone microstructure with quality of life (BDHQ) [day1]: Patients will be asked to complete a short debriefing questionnaire covering questions ( BDHQ)
  • Comparing bone microstructure with quality of life (FRAX) [day1]: Patients will be asked to complete a short debriefing questionnaire covering questions (FRAX)

+Eligibility

Sex: All, ages: 60 Years to 90 Years, accepts healthy volunteers

Inclusion Criteria:

* At least 5 years have elapsed since DG or TG due to gastric cancer
* Provide signed informed consent

Exclusion Criteria:

* pregnancy
* Current use of the following osteoporosis agents; Teriparatide, Denosumab, and bisphosphonate
* Hyperthyroidism
* Hyperparathyroidism
* Present malignancy (except in situ carcinoma)
* Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy
* Other diseases which affect bone metabolism
* Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures
* Received > 3 months (or equivalent) of osteoporosis treatment
* Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).

+Locations (1)

FacilityCityCountryStatus
Nagasaki University HospitalNagasakiJapanRecruiting

+Investigators

  • Shinichiro Kobayashi, MD, Principal investigator, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences,

My Notes